Anixa Biosciences, Inc. (ANIX)
NASDAQ: ANIX · Real-Time Price · USD
2.900
-0.010 (-0.34%)
Oct 9, 2026, 4:00 PM EDT - Market closed
Anixa Biosciences Employees
Anixa Biosciences had 4 employees as of October 31, 2025. The number of employees decreased by 1 or -20.00% compared to the previous year. That makes Anixa Biosciences the 41,978th largest employer in the world and 6,631st in the United States.
Employees
4
Change (1Y)
-1
Growth (1Y)
-20.00%
Revenue / Employee
n/a
Profits / Employee
-$2,595,500
Market Cap
100.82M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Oct 31, 2025 | 4 | -1 | -20.00% | 4 | 0 |
| Oct 31, 2024 | 5 | 0 | - | 5 | 0 |
| Oct 31, 2023 | 5 | 0 | - | 4 | 1 |
| Oct 31, 2022 | 5 | 0 | - | 4 | 1 |
| Oct 31, 2021 | 5 | 1 | 25.00% | 4 | 1 |
| Oct 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Oct 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Oct 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Oct 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Oct 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| PolyPid | 75 |
| OnKure Therapeutics | 45 |
| Vivani Medical | 42 |
| Milestone Pharmaceuticals | 38 |
| Biomea Fusion | 37 |
| Corbus Pharmaceuticals Holdings | 36 |
| Aardvark Therapeutics | 28 |
| Black Diamond Therapeutics | 21 |
ANIX News
- 4 days ago - Anixa Biosciences reports first case of stable disease in CAR-T trial - TheFly
- 4 days ago - Anixa Biosciences Announces First Case of Stable Disease for Three Months in Ovarian Cancer CAR-T Clinical Trial - PRNewsWire
- 8 days ago - Anixa Biosciences says second patient treated in CAR-T ovarian cancer trial - TheFly
- 8 days ago - Anixa Biosciences Announces Treatment of Second Patient in the Fifth Cohort of its Ovarian Cancer CAR-T Clinical Trial - PRNewsWire
- 17 days ago - Anixa Biosciences price target lowered to $6 from $7 at H.C. Wainwright - TheFly
- 18 days ago - Anixa Biosciences granted first Australian patent for breast cancer vaccine - TheFly
- 18 days ago - Anixa Biosciences Granted First Australian Patent for its Breast Cancer Vaccine, Broadening Global Protection Through 2040 - PRNewsWire
- 23 days ago - Anixa Biosciences Appoints UPenn's Dr. Carmen Guerra to Cancer Business Advisory Board - PRNewsWire